Our current study revealed the important role of CD37 gene in clinical outcomes in AML patients, and provided the rationale to identify CD37 as a valuable biomarker and develop strategies to target CD37 for AML therapy. The gene discussed is CD37; the disease is acute myeloid leukemia.